Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J. van den Bent, Johan M. Kros, Brigitta G. Baumert et al.|The Lancet|2017Cited by 401
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J. van den Bent, Brigitta G. Baumert, C. Mircea S. Tesileanu et al.|The Lancet Oncology|2021Cited by 333
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON TrialC. Mircea S. Tesileanu, Martin J. van den Bent, Marc Sanson et al.|Clinical Cancer Research|2022Cited by 74
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC. Mircea S. Tesileanu, Pim J. French, Martin J. van den Bent et al.|Neuro-Oncology|2021Cited by 66
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC. Mircea S. Tesileanu, Pim J. French, Wies Vallentgoed et al.|Acta Neuropathologica|2021Cited by 60